MRC Technology Launches Small Molecule Compound Library Access Scheme
News Sep 20, 2012
MRC Technology has announced the launch of a scheme under which it will provide access to a representative subset of 9,000 compounds from its 150,000 small molecule compound library to academic research institutes free of charge.
The scheme has been launched by MRC Technology to provide academics with a high quality compound library for screening, to reduce academic spend on libraries less suited to screening, and to encourage groups to tap into MRC Technology’s drug discovery expertise for research programmes.
Under the terms of the scheme, participating academics will receive the 9,000 compounds in plate format and in return MRC Technology will have first refusal on collaboration agreements for any drug development programmes resulting from screens of the compound library.
Assay data will be jointly owned by MRC Technology and the research institute, giving MRC Technology a better understanding of how its library is performing against a diverse range of targets and enabling further enhancement of the library through an iterative process.
MRC Technology’s compound library has been built and curated by its medicinal chemistry and computational chemistry scientists.
The library includes 100,000 high quality, diverse, drug-like compounds with hit-like properties, with an additional 50,000 compounds in subsets targeted to specific protein classes.
The 9,000 compounds available through the scheme have been chosen to represent a cross-section of the full library.
Institutes joining the scheme will also benefit from access to advice on suitable assay design and screening formats, and optimization of screening hits, from MRC Technology’s team of scientists.
“We have seen an increase in assay throughput within academic research institutes, due to the availability of affordable small-scale robotics,” said Justin Bryans, Director of Drug Discovery at MRC Technology.
Bryans continued, “By offering access to our compound library with no fees attached, our aim is to stimulate drug discovery within the academic field by enabling these laboratories to carry out high quality, medium throughput screens and to potentially further develop any hits in collaboration with MRCT.”
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018